Agile Therapeutics, Inc. (AGRX) insiders have most recently took part in a trading activity. On Aug 25, 2017 Selman Renee, Chief Commercial Officer bought 7,250 shares having total worth of $24,288 at the price of $3.35 per share, following the transaction a total of 60,583 shares owned by Selman Renee. Before this latest buy, Selman Renee purchased AGRX at 1 other times during the past twelve months, for a total investment of $196,265 at an average of $3.68 per share.
On the same day, Altomari Alfred, Chairman & Chief Executive Off bought 10,000 shares having total worth of $33,400 at the price of $3.34 per share, following the transaction a total of 161,587 shares owned by Altomari Alfred. Before this latest buy, Altomari Alfred purchased AGRX at 1 other times during the past twelve months, for a total investment of $35,100 at an average of $3.51 per share.
Furthermore, over the past 12 months , the stock was traded 2 times by insiders. an employee of the company was the buyer in 2 instances.
Agile Therapeutics, Inc. (AGRX) last announced its earnings results on Jul 28, 2017. The company reported -0.26 earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company posted -0.29 earnings per share.
|earnings per share||-0.26||-0.26||-0.29||-0.27|
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018